- Home
- Products
- Customized ADCs
- CEACAM5
- Anti-CEACAM5 (Altumomab)-MC-Vc-PAB-MMAE ADC
Anti-CEACAM5 (Altumomab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-971)
This ADC product is comprised of an anti-CEACAM5 monoclonal antibody conjugated via a MC-Vc linker to MMAE. The MMAE is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAE binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.
- ADC Target
- ADC Antibody
- ADC Linker
- ADC payload drug
- Name
- CEACAM5
- Alternative Names
- CEACAM5; carcinoembryonic antigen-related cell adhesion molecule 5; CEA; CD66e; meconium antigen 100; DKFZp781M2392;
- Target Entrez Gene ID
- 1048
- Target UniProt ID
- P06731
- Overview
- This gene encodes a cell surface glycoprotein that represents the founding member of the carcinoembryonic antigen (CEA) family of proteins. The encoded protein is used as a clinical biomarker for gastrointestinal cancers and may promote tumor development through its role as a cell adhesion molecule. Additionally, the encoded protein may regulate differentiation, apoptosis, and cell polarity. This gene is present in a CEA family gene cluster on chromosome 19. Alternative splicing results in multiple transcript variants.
- Overview
- Anti-CEACAM5 IgG1 antibody, altumomab
- Generic name
- Altumomab
- Host animal
- Mouse
- Species Reactivity
- Human
- Name
- MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl)
- Description
- Peptide linkers, belonging to Enzymatically cleavable linkers, combine greater systemic stability with rapid enzymatic release of the drug in the target cell. The scission of peptidic bonds relies on lysosomal proteolytic enzymes, which have very low activities in blood due to endogenous inhibitors and the unfavorably high pH value of blood.
- Name
- MMAE
- Description
- Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-ANGPTL3-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-2327)
- Anti-CD74-SMCC-DM1 ADC (CAT#: ADC-W-2548)
- Anti-MUC16 (Oregovomab)-SPDB-DM4 ADC (CAT#: ADC-W-1647)
- Anti-ANGPT2 SPDB-DM4 ADC ADC (CAT#: ADC-W-663)
- Anti-OxLDL-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-2095)
- Anti-CD3E (Pasotuxizumab)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-2424)
- Anti-ERBB2 (Trastuzumab)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-2596)
- Anti-IL23A (Guselkumab)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-1350)
- Anti-MSLN (Anetumab )-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-2563)
- Anti-FCER2 (Lumiliximab)-MC-MMAF ADC (CAT#: ADC-W-1138)
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-W-971. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
Same Linker
Same Payload
CAT# | Product Name | Linker | Payload |
ADC-W-2579 | Anti-CEACAM5-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
ADC-W-972 | Anti-CEACAM5 (Altumomab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
ADC-W-970 | Anti-CEACAM5 (Altumomab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
ADC-W-472 | Anti-CEACAM5-Phy-lys-SN-38 ADC | Phy-lys (Phenylalanine-lysine) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
ADC-W-969 | Anti-CEACAM5 (Altumomab)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
CAT# | Product Name | Linker | Payload |
ADC-W-2613 | Anti-MS4A1 (Rituximab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
ADC-W-2623 | Anti-NCAM1 (Lorvotuzumab )-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
ADC-W-2592 | Anti-EGFR (Cetuximab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
ADC-W-2608 | Anti-ITGB3 (Tadocizumab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
ADC-W-2596 | Anti-ERBB2 (Trastuzumab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
CAT# | Product Name | Linker | Payload |
ADC-W-2551 | Anti-CD74-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
ADC-W-2601 | Anti-GPNMB (Glembatumumab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
ADC-W-2613 | Anti-MS4A1 (Rituximab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
ADC-W-2586 | Anti-EGFR (Zalutumumab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
ADC-W-2574 | Anti-SLC34A2 (Lifastuzumab )-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.